Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02303951 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC(NEO-VC) | terminated | Phase 2 | 47 | University Hospital TuebingenOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | terminated | Phase 2 | 6 | University Hospital TuebingenOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01683188 | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma(PROCLIVITY01) | terminated | Phase 4 | 53 | Clinigen, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00515528 | Vaccination Plus Ontak in Patients With Metastatic Melanoma | terminated | Phase 2 | 17 | University of ChicagoOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00003509 | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | terminated | Phase 1 / Phase 2 | 6 | Institut Claudius RegaudOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03241927 | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | terminated | Phase 2 | 1 | Nina BhardwajOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | terminated | Phase 3 | 134 | AB ScienceINDUSTRY | 7 | Nov 5, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02410863 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma(BOTTOM) | terminated | Phase 2 | 10 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT01942993 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | terminated | Phase 2 | 3 | Philip FriedlanderOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT00505635 | Biochemotherapy With Temozolomide for Metastatic Melanoma | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | terminated | Phase 1 | 22 | BioNTech US Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT03825913 | 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma | terminated | N/A | 1 | University of MiamiOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT02889861 | IMCgp100-401 Rollover Study | terminated | Phase 2 | 3 | Immunocore LtdINDUSTRY | 2 | Jul 27, 2020 | clinicaltrials |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | terminated | Phase 2 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT00003060 | Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 | 6 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03674502 | Safety of ADU-1604 in Adults With Metastatic Melanoma | terminated | Phase 1 | 4 | Aduro Biotech, Inc.INDUSTRY | 2 | May 26, 2020 | clinicaltrials |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 1 | 11 | NYU Langone HealthOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | terminated | Phase 1 / Phase 2 | 3 | Craig L Slingluff, JrOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02718391 | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.(ACDC) | terminated | Phase 2 | 12 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | terminated | Phase 1 | 5 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03338777 | Suicide Plus Immune Gene Therapy for Advanced Melanoma(IGTM-101) | terminated | Early Phase 1 | 4 | Hospital Italiano de Buenos AiresOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | terminated | N/A | 98 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 23 | University of WashingtonOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | terminated | — | 3 | Philip SchanerOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2021source: clinicaltrials